探讨机器人辅助单孔腹腔镜根治性前列腺切除术（Single-port Robot-assisted Radical Prostatectomy， spRARP）治疗中高危前列腺癌（Prostate Cancer, PCa）患者的临床应用价值。方法：回顾性分析哈尔滨医科大学 附属第一医院 2021 年 6 月—2022 年 1 月行 spRARP 手术患者的临床资料和围手术期指标，所有患者术前均评估 为中高危 PCa。结果：本研究共纳入 8 例患者，平均年龄为 69.75（50~80）岁，平均体重指数（BMI）为 24.75 （17.96~28.34）kg/m2 ，平均 PSA 为 43.67（8.58~100）ng/ml，Gleason 评分平均为 7（6~8）分。手术均顺利完成， 未发生中转开腹或增加辅助通道。平均手术时间为 219.38（130~290）min，平均出血量 131.25（20~400）ml，术后 均未使用阿片类镇痛药物，术后 7d 拔除导尿管且术后即刻尿控良好。切缘 5 例为阴性，3 例为阳性，术后短期随访（1~ 6 个月）均无漏尿，均无切口部位疼痛及不适感。结论：spRARP 治疗中高危 PCa 安全、可行，该术式具有切口小、 术后恢复快、疼痛小等特点，但其远期疗效仍待进一步验证。

To investigate the clinical application of single-port robot-assisted radical prostatectomy (spRARP) in patients with medium or high-risk prostate cancer (PCa). Methods: Clinical data and perioperative parameters of patients under spRARP for medium or high-risk PCa in the First Affiliated Hospital of Harbin Medical University from June 2021 to January 2022 were collected and analyzed retrospectively. Results: 8 patients were selected in this study, with the average age of 69.75(50-80) years and mean body mass index (BMI) of 24.75(17.96-28.34)kg/m2 . The average PSA was 43.67(8.58-100) ng/ml, and the average Gleason score was 7 (6-8). All surgeries were successfully completed without conversion to laparotomy or adding auxiliary channels. The mean operative time was 219.38 (130-290)min, with an average blood loss of 131.25(20-400)ml. No opiate analgesics were used after operation. The catheter was removed 7 days after operation and immediate postoperative urinary continence was satisfied. Negative margins were found in 5 cases and positive margins in 3 cases. There was no leakage of urine during the short-term followup (1-6 months) after operation, and no pain or discomfort occurred at the incision site. Conclusion: spRARP is safe and feasible in treating moderate or high risk PCa, but further studies should be done to confirm its long-term efficacy.

收稿日期：2022-02-28  录用日期：2022-06-25 

Received Date: 2022-02-28  Accepted Date: 2022-06-25 

基金项目：哈尔滨医科大学附属第一医院杰出青年医学人才培养资助项目（HYD2020JQ0020） Foundation Item: Youth Medical Talent Cultivation Founding Project of the First Affiliated Hospital of Harbin Medical University(HYD2020JQ0020) 

通讯作者：王春阳，Email：435427896@qq.com 

Corresponding Author: WANG Chunyang, Email: 435427896@qq.com 

引用格式：王越，苏子良，贾光，等 . 机器人辅助单孔腹腔镜根治性前列腺切除术在中高危患者中的应用 [J]. 机器人外科学杂志（中 英文），2022，3（6）：451-455. 

Citation: WANG Y, SU Z L, JIA G, et al. Application of single-port robot-assisted laparoscopic radical prostatectomy in medium or high-risk prostate cancer[J]. Chinese Journal of Robotic Surgery, 2022, 3(6): 451-455.

[1] Alvarez-Ossorio-Rodal A, Padilla-Fernandez B, MullerArteaga C A, et al. Impact of organ confined prostate cancer treatment on quality of life[J]. Actas Urol Esp (Engl Ed), 2020, 44(9): 630-636.

[2] Costello A J. Considering the role of radical prostatectomy in 21st century prostate cancer care[J]. Nat Rev Urol, 2020, 17(3): 177-188.

[3] Oberlin D T, Flum A S, Lai J D, et al. The effect of minimally invasive prostatectomy on practice patterns of American urologists[J]. Urol Oncol, 2016, 34(6): 251-255. 

[4] Fahmy O, Fahmy U A, Alhakamy N A, et al. Singleport versus multiple-port robot-assisted radical prostatectomy: a systematic review and meta-analysis[J]. J Clin Med, 2021, 10(24): 5723. [5] JU G Q, WANG Z J, SHI J Z, et al. A comparison of perioperative outcomes between extraperitoneal robotic single-port and multiport radical prostatectomy with the da Vinci Si Surgical System[J]. Asian J Androl, 2021, 23(6): 640-647.

[6] Moris L, Cumberbatch M G, Van den Broeck T, et al. Benefits and risks of primary treatments for highrisk localized and locally advanced prostate cancer: an international multidisciplinary systematic Review[J]. Eur Urol, 2020, 77(5): 614-627.

[7] Porpiglia F, Morra I, Lucci C M, et al. Randomised controlled trial comparing laparoscopic and robotassisted radical prostatectomy[J]. Eur Urol, 2013, 63(4): 606-614.

[8] Fossati N, Willemse P M, Van den Broeck T, et al. The Benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review[J]. Eur Urol, 2017, 72(1): 84-109.

[9] Violette P D, Mikhail D, Pond G R, et al. Independent predictors of prolonged operative time during roboticassisted radical prostatectomy[J]. J Robot Surg, 2015, 9(2): 117-123.

[10] Kaneko G, Miyajima A, Yazawa S, et al. What is the predictor of prolonged operative time during laparoscopic radical prostatectomy?[J]. Int J Urol, 2013, 20(3): 330-336.

[11] Moul J W, Sun L, Wu H, et al. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)- era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database[J]. Urol Oncol, 2003, 21(6): 447-455. 

[12] Murakami T, Otsubo S, Namitome R, et al. Clinical factors affecting perioperative outcomes in robotassisted radical prostatectomy[J]. Mol Clin Oncol, 2018, 9(5): 575-581.

[13] Kocarek J, Heracek J, Cermak M, et al. Robotic-assisted radical prostatectomy-results of 1 500 surgeries[J]. Rozhl Chir, 2017, 96(2): 75-81.

[14] Yang C W, Wang H H, Hassouna M F, et al. Prediction of a positive surgical margin and biochemical recurrence after robot-assisted radical prostatectomy[J]. Sci Rep, 2021, 11(1): 14329.

[15] Sundi D, Tosoian J J, Nyame Y A, et al. Outcomes of very high-risk prostate cancer after radical prostatectomy: validation study from 3 centers[J]. Cancer, 2019, 125(3): 391-397.